Olfr68, encoded by the Or52a5 gene, is a member of the olfactory receptor family in Mus musculus, belonging to the broader class of G-protein-coupled receptors (GPCRs). These receptors are pivotal for the sense of smell, detecting odorant molecules in the nasal epithelium and initiating a neuronal response that results in the perception of odors. Olfactory receptors, including Olfr68, are characterized by their 7-transmembrane domain structure, which is a common feature among many neurotransmitter and hormone receptors. They are responsible for the recognition and G protein-mediated transduction of odorant signals, a process that typically involves the activation of downstream signaling pathways, often mediated by changes in intracellular messengers like cyclic AMP (cAMP). Inhibiting Olfr68 poses a significant challenge due to the intricacy of GPCR signaling pathways and the lack of direct, specific inhibitors. Therefore, potential indirect inhibitors are considered, which modulate related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists, such as propranolol, atenolol, and metoprolol, reduce cellular cAMP levels, crucial in GPCR signaling. This reduction in cAMP could indirectly influence the signaling pathways of GPCRs, potentially affecting the function of olfactory receptors like Olfr68. Furthermore, calcium channel blockers like nifedipine and verapamil alter intracellular calcium levels, another vital element in GPCR signaling. These changes in calcium dynamics might indirectly affect the function of GPCRs, including Olfr68.
Targeting other GPCR pathways, such as those modulated by angiotensin II receptors, offers another indirect method to influence olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting the function of receptors like Olfr68. Additionally, alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine could also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In summary, the indirect inhibition of Olfr68 involves an understanding of GPCR biology and the interconnected nature of cellular signaling pathways. The chemicals listed provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr68. While direct inhibition remains a significant challenge, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, lowers cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr68. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, which could indirectly influence GPCR signaling pathways and impact Olfr68 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially influencing Olfr68. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr68. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr68. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr68. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr68. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr68. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr68. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr68. | ||||||